What is the appropriate management for a patient with non‑specific gastritis, H. pylori‑negative, who has iron deficiency and vitamin B12 deficiency?

Management of Non-Specific Gastritis with Iron and Vitamin B12 Deficiency (H. pylori Negative)

This patient requires comprehensive GI evaluation with bidirectional endoscopy and small bowel biopsies to identify the underlying cause of both deficiencies, followed by targeted iron and vitamin B12 replacement therapy. 1, 2

Diagnostic Workup Priority

Immediate Testing Required

Even though H. pylori is negative, non-specific gastritis with dual micronutrient deficiencies demands investigation for:

• Autoimmune gastritis (AIG) - This is critical as AIG patients have an 11.5-fold increased risk of vitamin B12 deficiency and 2.9-fold increased risk of iron deficiency compared to controls 3. Check:

  • Anti-parietal cell antibodies
  • Anti-intrinsic factor antibodies
  • Serum gastrin level 2

• Celiac disease - Initial serologic testing with anti-tissue transglutaminase antibodies (plus IgA level to exclude IgA deficiency) 4, 5. If positive, proceed to small bowel biopsy during endoscopy.

• Chronic atrophic gastritis - The combination of iron and B12 deficiency strongly suggests corpus-predominant atrophic gastritis 2, 3. Topographical gastric biopsies are essential even without H. pylori, as 20-27% of unexplained iron deficiency cases have autoimmune gastritis 6.

Why This Matters

Iron deficiency typically precedes vitamin B12 deficiency in autoimmune gastritis by many years, often presenting in younger patients before pernicious anemia develops 6, 7. The loss of parietal cells reduces both intrinsic factor (causing B12 malabsorption) and gastric acid (impairing iron absorption from food) 7.

Iron Replacement Strategy

Initial Approach

Start with oral iron supplementation: ferrous sulfate 200 mg once daily (65 mg elemental iron) taken on an empty stomach 1. This lower, once-daily dosing improves tolerance compared to traditional three-times-daily regimens.

• Add vitamin C 500 mg with iron to enhance absorption 4, 8
• Expect hemoglobin rise of 2 g/dL within 3-4 weeks 4
• If no response after 2 weeks, this predicts treatment failure with 90% sensitivity 1

When to Switch to IV Iron

Consider intravenous iron if:

• Intolerance to at least two oral iron preparations 4
• Confirmed malabsorption (e.g., celiac disease, severe atrophic gastritis) 1
• No hemoglobin response after 2 weeks of adequate oral therapy 1
• Moderate to severe anemia (Hb <100 g/L) with active inflammation 9

Common pitfall: Don't continue ineffective oral iron for months. Early monitoring at 2-4 weeks identifies non-responders who need alternative therapy 1.

Vitamin B12 Replacement

For patients with confirmed B12 deficiency and atrophic gastritis:

• Parenteral B12 is preferred when corpus-predominant atrophy is documented, as oral absorption is unreliable 2
• Standard regimen: 1000 mcg IM weekly for 4-8 weeks, then monthly maintenance
• Monitor response with repeat B12 levels and complete blood count

If autoimmune gastritis is confirmed, lifelong B12 supplementation is required 2.

Surveillance Considerations

Once atrophic gastritis is identified:

• Endoscopic surveillance every 3 years for advanced atrophic gastritis (extensive anatomic involvement) 2
• Screen for type 1 gastric neuroendocrine tumors during surveillance 2
• Monitor for recurrent iron deficiency every 3 months initially, then periodically 1
• Check for concomitant autoimmune thyroid disease if AIG is confirmed 2

Treatment Failure Investigation

If anemia doesn't resolve by 6 months despite treatment 4:

• Reassess compliance with iron therapy
• Confirm diagnosis (check for continued blood loss, hemolysis, bone marrow pathology)
• Evaluate for concurrent folate deficiency 1
• Consider video capsule endoscopy if bidirectional endoscopy was negative 5

Key Clinical Pearls

The presence of both iron AND vitamin B12 deficiency in H. pylori-negative gastritis is not coincidental - it strongly suggests corpus-predominant atrophic gastritis, most likely autoimmune in etiology 3, 7. This pattern warrants aggressive investigation rather than empiric supplementation alone, as these patients require cancer surveillance and have specific long-term management needs 2.

The ferritin threshold for diagnosing iron deficiency may need adjustment upward (to 100 μg/L) if any inflammation is present, as ferritin is an acute phase reactant 1, 9. Transferrin saturation <20% helps confirm true iron deficiency in this context 1.